^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MYCL expression

    i
    Other names: MYCL, MYCL Proto-Oncogene BHLH Transcription Factor, Class E Basic Helix-Loop-Helix Protein 38, Myc-Related Gene From Lung Cancer, Protein L-Myc-1, Protein L-Myc, BHLHe38 , MYCL1, LMYC, V-Myc Avian Myelocytomatosis Viral Oncogene Homolog 1 Lung Carcinoma Derived 2, V-Myc Avian Myelocytomatosis Viral Oncogene Lung Carcinoma Derived Homolog 3, V-Myc Myelocytomatosis Viral Oncogene Homolog 1 Lung Carcinoma Derived 3, V-Myc Myelocytomatosis Viral Oncogene Homolog, L-Myc-1 Proto-Oncogene, L-Myc Protein 2 Oncogene Lmyc, BHLHE38, L-Myc
    Entrez ID:
    4610
    Related biomarkers:
    Expression
    CNA
    2d
    A MYC family switch: L-MYC drives and maintains neuroendocrine lineage programs in prostate cancer. (PubMed, Neoplasia)
    Mechanistically, MYC suppression is associated with transcriptional regulation by ASCL1, while MYCL upregulation appears to occur within a permissive epigenetic landscape rather than through genomic amplification. Together, these findings identify MYCL as a lineage-specific regulator that drives and maintains neuroendocrine identity and define a MYC family regulatory switch in which MYCL replaces MYC to stabilize neuroendocrine lineage programs in advanced prostate cancer.
    Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1)
    |
    MYCL expression
    3ms
    A MYC Family Switch: L-MYC Drives and Maintains Neuroendocrine Lineage Programs in Prostate Cancer. (PubMed, bioRxiv)
    We further identify ASCL1 and INSM1 as upstream regulators of MYCL, establishing a conserved neuroendocrine transcriptional axis. Together, these findings define MYCL as a lineage-specific regulator that drives neuroendocrine identity and plasticity in advanced prostate cancer.
    Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1)
    |
    MYCL expression
    almost3years
    Alterations and Co-Occurrence of C-MYC, N-MYC, and L-MYC Expression are Related to Clinical Outcomes in Various Cancers. (PubMed, Int J Stem Cells)
    Multivariate analysis also confirmed that co-expression of MYC/MYCL/MYCN was significantly associated with the prognosis of lung, gastric, liver, and breast cancers. Taken together, our results demonstrate that the MYC family can function not only as an oncogene but also as a tumor suppressor gene in various cancers, which could be used to develop a novel approach to cancer treatment.
    Clinical data • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    MYC expression • MYCL expression